Novo Nordisk A/S $NVO Shares Sold by PFG Investments LLC

PFG Investments LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 40.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,693 shares of the company’s stock after selling 9,268 shares during the period. PFG Investments LLC’s holdings in Novo Nordisk A/S were worth $760,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Revolve Wealth Partners LLC boosted its stake in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock valued at $4,312,000 after acquiring an additional 10,758 shares during the period. Sivia Capital Partners LLC boosted its position in Novo Nordisk A/S by 18.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Avior Wealth Management LLC boosted its position in Novo Nordisk A/S by 7.9% in the 2nd quarter. Avior Wealth Management LLC now owns 19,152 shares of the company’s stock worth $1,322,000 after purchasing an additional 1,402 shares in the last quarter. Finally, Sound Income Strategies LLC grew its stake in shares of Novo Nordisk A/S by 194.5% during the 2nd quarter. Sound Income Strategies LLC now owns 2,692 shares of the company’s stock worth $186,000 after purchasing an additional 1,778 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. HSBC reiterated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, January 9th. BMO Capital Markets set a $57.00 target price on Novo Nordisk A/S in a research report on Monday. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $57.79.

Novo Nordisk A/S Trading Up 2.7%

NVO stock opened at $63.96 on Tuesday. Novo Nordisk A/S has a 12-month low of $43.08 and a 12-month high of $93.80. The business’s 50-day moving average is $52.44 and its 200 day moving average is $54.54. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. The stock has a market cap of $285.58 billion, a price-to-earnings ratio of 18.59 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.